Skip to main content
. Author manuscript; available in PMC: 2010 Feb 10.
Published in final edited form as: Vaccine. 2009 May 29;27(43):6088. doi: 10.1016/j.vaccine.2009.05.016

Fig. 4.

Fig. 4

Summed ELISPOT responses to HIV-1 antigens in subjects who received DC + CP-HIV (group A) vs. subjects who received CP-HIV alone (group B). A responder is defined as a subject who has a ≥3-fold increase in summed ELISPOT response, that is also ≥30 spot-forming cells/106 peripheral blood mononuclear cells, to HIV-1 antigens from baseline to the maximum pre-ATI time point (i.e. maximum ELISPOT level at week 3, 7 or between weeks 16–19). ATI: analytic treatment interruption.